Chen Charles H
Synthetic Biology Group, Research Laboratory of Electronics, Massachusetts Institute of Technology (MIT), Cambridge, MA, United States.
Prog Mol Biol Transl Sci. 2025;212:67-116. doi: 10.1016/bs.pmbts.2024.10.005. Epub 2024 Nov 1.
Membrane-active peptides are found in many living organisms and play a critical role in their immune systems by combating various infectious diseases. These host defense peptides employ multiple mechanisms against different microorganisms and possess unique functions, such as anti-inflammatory and immunomodulatory effects, often working in synergy with other antimicrobial agents. Despite extensive research over the past few decades and the identification of thousands of sequences, only a few have been successfully applied in clinical settings and received approval from the U.S. Food and Drug Administration. In this chapter, we explore all peptide therapeutics that have reached the market, as well as candidates in preclinical and clinical trials, to understand their success and potential applications in cancer therapy. Our findings indicate that at least four membrane-active peptide drugs have progressed to preclinical or clinical phases, dmonstrating promising results for cancer treatment. We summarize our insights in this chapter, highlighting the potential of membrane-active anticancer peptide therapeutics and their applications as targeting ligands in various biomedical fields.
膜活性肽存在于许多生物体中,通过对抗各种传染病在其免疫系统中发挥关键作用。这些宿主防御肽采用多种机制对抗不同的微生物,并具有独特的功能,如抗炎和免疫调节作用,通常与其他抗菌剂协同发挥作用。尽管在过去几十年中进行了广泛的研究,并鉴定出了数千个序列,但只有少数几个已成功应用于临床环境并获得了美国食品药品监督管理局的批准。在本章中,我们探讨了所有已上市的肽类疗法以及临床前和临床试验中的候选药物,以了解它们在癌症治疗中的成功之处和潜在应用。我们的研究结果表明,至少有四种膜活性肽药物已进入临床前或临床阶段,显示出在癌症治疗方面的 promising 结果。我们在本章中总结了我们的见解,强调了膜活性抗癌肽疗法的潜力及其作为各种生物医学领域靶向配体的应用。